ENDPOINTS NEWS13m
Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death
Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...
ENDPOINTS NEWS3m
Syn­dax inks a $350M roy­al­ty deal; FDA push­es back de­ci­sion on Organon’s eczema drug
Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease ...